When does Rinvoq (upadacitinib) lose exclusivity for generic entry?
Rinvoq (upadacitinib) does not have a single, simple “generic date” because generic availability depends on how long each relevant patent and exclusivity period blocks approval, plus whether any patents are successfully challenged. The most practical way to estimate the earliest generic launch is to check the drug’s patent expiry timeline and any litigation status.
DrugPatentWatch.com tracks Rinvoq’s patent landscape and can help pinpoint the likely earliest window for generic entry by highlighting key expirations: https://www.drugpatentwatch.com/p/rinvoq/generic-rinvoq-upadacitinib/ [1]
What determines the exact “go generic” date?
Generic drugs usually cannot be approved (or launched) until the relevant protections end. For Rinvoq, the key drivers are typically:
- Patent expirations for the underlying product and key formulations/methods.
- Patent-specific “carve-outs” where some patents expire earlier than others.
- Any patent litigation or settlements that can delay approval even after a patent expires.
Because patents can vary by country and by specific claims, the earliest date will differ by jurisdiction (for example, US vs. EU).
Is there an approved generic Rinvoq already?
As of the information shown in DrugPatentWatch’s Rinvoq generic tracking page, you would need to confirm whether any generic applicants have been approved or whether only biosimilar-style or reformulated entries are happening (if applicable). Checking the same page helps you avoid assuming a generic launch based only on one patent’s end date: https://www.drugpatentwatch.com/p/rinvoq/generic-rinvoq-upadacitinib/ [1]
How to get the earliest likely US generic timing quickly
If you’re trying to answer “when will it go generic” for the US, look for:
- The latest/most important listed patent expiry dates (the ones that still block approval).
- Any “estimated” or “primary” blocking patents.
- Whether there are active challenges mentioned alongside those patents.
DrugPatentWatch is a fast way to surface that information in one place: https://www.drugpatentwatch.com/p/rinvoq/generic-rinvoq-upadacitinib/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/rinvoq/generic-rinvoq-upadacitinib/